Table 2.
Univariate and multivariate analyses for overall survival in CRC
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Gender | ||||
| Female | 1 | |||
| Male | 1.23 (0.98–1.50) | 0.076 | ||
| Stage | ||||
| I | 1 | 1 | ||
| II | 1.70 (0.94–3.10) | 0.082 | 1.45 (0.79–2.66) | 0.225 |
| III | 2.34 (1.28–4.25) | 0.006 | 1.74 (0.95–3.21) | 0.074 |
| IV | 8.26 (4.50–15.18) | < 0.001 | 6.07 (3.25–11.35) | < 0.001 |
| Location | ||||
| Left colon, rectum | 1 | |||
| Right colon | 1.13 (0.90–1.42) | 0.304 | ||
| Microsatellite | ||||
| MSI | 1 | |||
| MSS | 1.11 (0.78–1.58) | 0.566 | ||
| CMS | ||||
| CMS1 | 1 | 1 | ||
| CMS2 | 0.97 (0.67–1.38) | 0.848 | 0.94 (0.63–1.39) | 0.743 |
| CMS3 | 0.70 (0.42–1.16) | 0.171 | 0.67 (0.37–1.17) | 0.160 |
| CMS4 | 1.45 (1.00–2.11) | 0.049 | 1.10 (0.74–1.64) | 0.625 |
| Indeterminate | 1.55 (0.98–2.46) | 0.064 | 1.41 (0.87–2.29) | 0.159 |
| KRAS status | ||||
| Wild-type | 1 | 1 | ||
| Mutated | 1.27 (1.01–1.61) | 0.043 | 1.29 (1.00–1.66) | 0.048 |
| BRAF status | ||||
| Wild-type | 1 | |||
| Mutated | 1.23 (0.85–1.79) | 0.28 | ||
| TP53 status | ||||
| Wild-type | 1 | |||
| Mutated | 1.20 (0.92–1.57) | |||
| CIMP | ||||
| Low | 1 | |||
| High | 1.14 (0.83–1.57) | |||
| Group | ||||
| Group I + II | 1 | 1 | ||
| Group III | 1.68 (1.30–2.17) | < 0.001 | 1.41 (1.05–1.90) | 0.023 |
| Group IV | 1.20 (0.90–1.60) | 0.223 | 1.06 (0.77–1.48) | 0.709 |
GSE39582 and TCGA samples of CRC were pooled for this analysis
Abbreviations: HR hazard ratio